{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-000436","form_type":"8-K","ticker":"GLUE","cik":"0001826457","company_name":"Monte Rosa Therapeutics, Inc.","filed_at":"2023-01-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.849915+00:00","generated_at":"2026-06-20T18:10:59.453532+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Monte Rosa Therapeutics outlines 2023 milestones; MRT-2359 Fast Track designation from FDA","bullets":["MRT-2359 granted FDA Fast Track for previously treated metastatic NSCLC with L-MYC or N-MYC expression.","Initial Phase 1 data from ongoing Phase 1/2 trial of MRT-2359 expected in H2 2023.","Company anticipates nomination of multiple development candidates in 2023 across oncology, autoimmune, and inflammatory indications.","Presentation at J.P. Morgan Healthcare Conference on Jan 11, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-000436","json":"https://secwatch.observer/filing/0000950170-23-000436.json","markdown":"https://secwatch.observer/filing/0000950170-23-000436.md","text":"https://secwatch.observer/filing/0000950170-23-000436.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1826457/000095017023000436/0000950170-23-000436-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1826457/000095017023000436/glue-20230109.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T18:10:59.453532+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}